
Health Insurance CEO Pulls Back Curtain on Prior Auth Reform
This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox.
To commemorate the Fourth of July weekend, I have an American story for you. It's got all the Stars and Stripes: entrepreneurial spirits, bootstraps mentalities and the familiar drag of bureaucracy.
For the past several months, I've been working on this feature story about how patient advocacy groups are changing the pace of health care, working to find and fund cures for their loved ones' rare diseases (and, in some cases, their own).
What I found was a community of ordinary people doing extraordinary things—not because they had the time, training or resources, but because they had no other choice. Parents, spouses and patients have taken on roles once reserved for pharmaceutical executives and lab directors, plunging headfirst into grant writing, data sharing and even drug development.
These patient advocates are becoming increasingly important to the field of rare disease research, Dr. Dominique Pichard, director of the NIH's National Center for Advancing Translational Sciences' (NCATS) division of rare disease research and innovation, told me. Less than 5 percent of known rare diseases have an FDA-approved treatment available.
Research efforts tend to focus on impacting the most lives with the fewest resources, as grant funding is competitive and hard to come by. But this means that many rare diseases are left untouched. Conditions that impact fewer than 200,000 Americans are difficult to lobby for—and those that do garner attention still face challenges when looking to establish expert advisory panels or fill a clinical trial.
That's where patient advocacy groups come in, compiling data, educating providers and serving as connectors between small populations and large research institutions.
In some cases, their efforts have helped fast-track clinical trials. In others, they've secured the first-ever FDA-approved treatment for a rare disease. But while their success stories are remarkable, they also raise bigger questions: Should patients be expected to do this much? Should finding a cure for a devastating condition depend on how many calls a parent is willing to make or whether they can raise $5 million?
"[This work] is really important, but it has also created a pressure on families," Pichard said. "They feel like selling their assets, quitting their jobs and learning science is the only way [their] child can get a cure."
This piece explores that bittersweet tension between the promises and pressures of patient-led progress. I hope you'll give it a read this holiday weekend, and maybe share it with someone who, like the advocates featured, refuses to take "no" or "slow" for an answer.
Essential Reading
The FBI has uncovered $14.6 billion worth of fraudulent claims submitted to Medicare, Medicaid and other government health care programs , the agency said on Monday in conjunction with the Department of Justice (DOJ). The investigation resulted in 324 defendants being charged, including 96 medical professionals.
, the agency said on Monday in conjunction with the Department of Justice (DOJ). The investigation resulted in 324 defendants being charged, including 96 medical professionals. Now, the DOJ, FBI and HHS say they are collaborating to create a health care data fusion center that will help them identify, investigate and prosecute health care fraud.
that will help them identify, investigate and prosecute health care fraud.
And yesterday, the entities announced a DOJ-HHS False Claims Act Working Group, in which HHS will refer potential False Claims Act violations to the DOJ. Read more about the working group, its members and its goals here.
Microsoft AI unveiled new research demonstrating AI's abilities in sequential diagnostics. The company's new model-agnostic MAI Diagnostic Orchestrator (MAI-DxO) achieved 85.5 percent diagnostic accuracy—outperforming generalist physicians, who reached the correct diagnosis 20 percent of the time, on average.
The company's new model-agnostic MAI Diagnostic Orchestrator (MAI-DxO) achieved 85.5 percent diagnostic accuracy—outperforming generalist physicians, who reached the correct diagnosis 20 percent of the time, on average. The study has its limitations. Microsoft's panel of 21 U.S. and U.K. doctors had a median of 12 years of experience but were not allowed to use search engines, language models or other sources of medical information when interacting with SDBench. These tools are common in physicians' practices, with about 1 in 5 using generative AI and about 7 in 10 using search engines on a regular basis, according to recent research—so the human participants may have achieved higher diagnostic accuracy if allowed to access their typical suite of online resources. The report received mixed reviews, generating significant hype in the digital health care space but receiving pushback from skeptical physicians. I spoke with Microsoft AI CEO Mustafa Suleyman and Health Vice President Dr. Dominic King about the research ahead of its release. Get the exclusive scoop here.
The Joint Commission has launched "Accreditation 360," a project it says will set a "new standard" for health care accreditation —using data analytics to fine-tune its focus on benchmarking and outcomes. The reforms include an updated accreditation manual, a new certification program, and moves to improve transparency and streamline processes. The organization has removed 714 requirements from the hospital accreditation program.
Read all about The Joint Commission's dive into the digital era here, featuring exclusive insights from President and CEO Dr. Jonathan Perlin.
—using data analytics to fine-tune its focus on benchmarking and outcomes. The reforms include an updated accreditation manual, a new certification program, and moves to improve transparency and streamline processes. The organization has removed 714 requirements from the hospital accreditation program. Read all about The Joint Commission's dive into the digital era here, featuring exclusive insights from President and CEO Dr. Jonathan Perlin. Read all about The Joint Commission's dive into the digital era here, featuring exclusive insights from President and CEO Dr. Jonathan Perlin.
The Senate voted to advance President Donald Trump's One Big Beautiful Bill (H.R. 1) on Tuesday, approving nearly $1 trillion in proposed Medicaid cuts that would revoke health care coverage from at least 11.8 million Americans over the next decade.
(H.R. 1) on Tuesday, approving nearly $1 trillion in proposed Medicaid cuts that would revoke health care coverage from at least 11.8 million Americans over the next decade. The House Rules Committee advanced the Senate's proposed changes, andat the time of writing on Wednesday afternoon, House Republicans were gunning to approve the final version by July 4. In an opinion piece for The New York Times, Larry Levitt, executive vice president for health policy at KFF, wrote: "This Republican policy bill is effectively a partial repeal of the Affordable Care Act to help pay for tax cuts, and should it reach President Trump's desk, it would represent the biggest rollback in federal support for health coverage ever."
Pulse Check
Paul Markovich is the president and CEO of Ascendiun.
Paul Markovich is the president and CEO of Ascendiun.
BCBS
Paul Markovich is the president and CEO of Ascendiun, the nonprofit, ultimate parent company of Blue Shield of California, Blue Shield Promise Health Plan, Altais and Stellarus. He previously served as CEO of Blue Shield of California from 2013 to the end of 2024 and currently sits on the boards of the Blue Cross Blue Shield (BCBS) Association and America's Health Insurance Plans (AHIP).
On Tuesday, I connected with Markovich to discuss last week's prior authorization reforms, born from a roundtable with health insurance companies and backed by HHS and CMS.
Editor's Note: Some responses have been lightly edited for length and clarity.
AHIP and BCBS were involved in these reforms, and you sit on the boards of both. From your perspective, when did these conversations about changing the prior authorization process really begin?
They've been going on for probably the better part of a year behind the scenes with both trade groups. The plan was to develop these criteria and then go out and publicly announce them, but we [decided] we would love to get some positive feedback and support from the federal government. In particular, the Centers for Medicare and Medicaid Services is a pretty big customer and client on this one.
So we went to them and said, "Look, this is what we've come up with. This is what we're planning on doing. A, How do you feel about it? And B, Would you be willing to say you feel good about it in public?"
And they said, "You know what? We really like this, and before you go public, let's talk about this in more detail, and go out effectively together and talk about these changes."
That ultimately led to the announcement, but it was very much conceived and driven by the trade associations for the health plans.
The prior authorization process has been debated by physicians, hospitals, health plans and even the government for a number of years. What about this particular moment made it time to act and lean into reform?
It was really clear this was our top pain point with patients, with the physician community and hospitals as well. This was the thing that was causing the most frustration and friction in the system.
There was the sense that the status quo was problematic, and that at some point there would probably be a solution, or solutions that were developed. Then the question would be, who was going to develop them, and where was [reform] going to come from? Was it going to come from the federal government, state governments? All of those were possibilities.
And I think we all just recognized we can do a whole lot better than this, and we need to do a whole lot better than this—and we can either construct something that we feel would be impactful without being detrimental, or we can wait for someone else to develop a solution which might be impactful but could also be detrimental, depending on how it's crafted.
There have been various events along the way, various ups and downs in the political process, but eventually, this was too painful of a point to be left alone.
One of the reforms laid out in the pledge is the standardization of electronic prior authorization submissions. What has been holding up the digitization process, and what will be the greatest challenge going forward?
One of the biggest barriers to getting there—and it is going to be our biggest challenge going forward—is establishing and adopting standards for the real-time digital exchange of the information. And I know this from personal experience, because I've been a champion of creating a comprehensive digital health record for every American for many years. We managed to get a law passed in California that requires the sharing of data from physicians and hospitals to health plans: so we have actually created for our members a comprehensive, real time digital record in California, but it's in part thanks to that law and the requirement to share the data.
But what ends up happening most of the time in prior authorizations is the health plan will say, there are certain best practices in health care that have been researched, that clinicians agree upon. There's a consensus about what the model of care should be in this situation, and what [the provider is] proposing to do is not consistent with that.
But typically what happens is you [as a health plan] don't have all the information on the member. It's there in the medical record somewhere, but it hasn't been sent to the plan in a format that they need to say, "Yes, I can match this up. This patient has this diagnosis. Yes, their test results would indicate that they need this procedure or this drug. It's consistent with medical protocols."
So typically, we're missing information, and then a series of time (days, sometimes ) that goes by where we're faxing requests for information. That's been the biggest challenge in the pre-authorization process. When we announced as a plan back in the fall of last year (before these industry announcements) that we were going to a real-time digital solution for prior authorization, we did a little spoof video with me bashing the fax machine to smithereens, which you may find entertaining.
To me, that's the biggest thing, Alexis. It's getting standards and protocols down, getting that data available. How is it that the health plan can access that information on the patient, from the physician and hospital, and more broadly, from all of the care that they've had in their history of care? If we have access to all of that, there's absolutely no reason why these prior authorization decisions can't happen as quickly as your prior authorization decisions do on your credit card, and that's what we're shooting for. But what needs to happen is that digitization of the data and that real time sharing of it—and there's been challenges with that, historically.
C-Suite Shuffles
Oregon Health & Science University tapped Dr. Shereef Elnahal to serve as its sixth president after a lengthy national search. Previously, Elnahal was appointed by President Joe Biden as undersecretary for health at the VA.
tapped to serve as its sixth after a lengthy national search. Previously, Elnahal was appointed by President Joe Biden as undersecretary for health at the VA. Debra Jaeger is the first chief revenue officer at Mount Sinai , based in New York City. In the role, she'll be responsible for integrating revenue cycle operations across the health system, reducing variation in processes and eliminating silos.
is the first at , based in New York City. In the role, she'll be responsible for integrating revenue cycle operations across the health system, reducing variation in processes and eliminating silos. Rich Liekweg is retiring from his role as CEO of BJC Health System on October 1. Liekweg joined the St. Louis-based health system in 2009 and assumed the top role in 2018. He was instrumental to the health system's growth and oversaw its 2024 merger with Saint Luke's Health System in Kansas City. Nick Barto, current president of BJC, will succeed Liekweg.
Executive Edge
Dr. Jeffrey Giullian is the chief medical officer of DaVita Kidney Care.
Dr. Jeffrey Giullian is the chief medical officer of DaVita Kidney Care.
DaVita
Dr. Jeffrey Giullian is the chief medical officer of DaVita Kidney Care, which provides kidney care and dialysis services across the nation and works to transform the experience of the more than 35 million people in the U.S. that live with chronic kidney disease (CKD).
Giullian has been busy at DaVita, which is growing its value-based care arrangements and expanding access to kidney transplantation. (Last year, more than 8,200 DaVita patients received a kidney transplant, the company's highest number of annual transplants to date.) He also lives a full life outside of work, serving in an advisory capacity at the University of Colorado and the Denver Business School, and preparing to be an empty-nester when his daughter begins college at UCLA this fall.
For this week's Executive Edge, I connected with Giullian to learn how he juggles it all:
"Prioritizing health and wellness is something I take seriously—not just because of the demands of my role, but because I believe it's foundational to showing up as my best self, both professionally and personally. One of the ways I stay grounded is through running . It's a consistent part of my routine that gives me space to reflect, recharge, and maintain physical and mental clarity.
. It's a consistent part of my routine that gives me space to reflect, recharge, and maintain physical and mental clarity. "I also try to be intentional about how I spend my time outside of work. With my daughter preparing for college, my wife and I are focused on making the most of this chapter as a family. That means carving out time for meaningful experiences, even amid a full calendar. I've found that when I align my personal time with what matters most—family, movement and purpose-driven work—it becomes easier to maintain energy and perspective.
"Wellness, to me, isn't just about physical health. It's also about staying connected to a sense of purpose. When I feel aligned with the work I'm doing and the values I hold, I'm more energized, more present and more resilient in the face of challenges. That sense of purpose acts as a compass. It helps me make decisions about where to invest my time and energy, and it keeps me grounded when things get busy. Whether I'm contributing to meaningful change in health care or showing up for the people who matter most in my life, I've found that fulfillment comes from knowing that my actions are part of something larger."
This is a preview of Access Health—Tap here to get this newsletter delivered straight to your inbox.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Trump officials ‘secretly' changed US health data in ‘gender ideology' crackdown, researchers allege
The Trump administration quietly altered massive US health datasets to remove any mention of gender, according to a new analysis. Scientists around the world rely on health data from US government agencies like the Centers for Disease Control and Prevention (CDC). But since President Donald Trump took office in January, these agencies have been altering data labels, mostly without disclosure, according to the investigation published in The Lancet, a leading medical journal. The authors argue that the 'hidden' changes could cast doubt on the integrity of American science. The database edits 'might be politically motivated and [are] not transparent,' Dr Aaron Kesselheim, a professor at Harvard Medical School, and Janet Freilich, a law professor at Boston University, said in the paper. Related Will Trump's funding cuts help Europe lure top research talent from the US? Their analysis included 232 US health datasets that were edited from late January to late March, covering veterans' health care use, global tobacco consumption, stroke deaths, nutrition, exercise, and obesity. It did not include datasets that are updated on a regular basis. About half of these datasets were 'substantially altered' during the two-month period, but only 15 acknowledged that changes had been made, the study found. The parts of the datasets meant for these disclosures remained empty as of early May, the researchers said. In most of the edited datasets – 106 of them – the word 'gender' was swapped out for 'sex'. Related US demands that EU companies comply with anti-diversity order US agencies have not confirmed or explained the changes, but Freilich and Kesselheim suspect they were made to comply with a Trump order to remove 'messages that promote or otherwise inculcate gender ideology'. The executive order, issued on Trump's first day in office, said it aimed to restore 'biological truth' to US agencies, and set a national policy 'to recognise two sexes, male and female,' they said. It was part of a flurry of activity to clamp down on LGBTQ protections. Some data was initially removed from federal websites, but was largely restored due to a court order. Related Trump administration's funding freeze for foreign medical research to hit European scientists The Lancet analysis indicates that not all changes were reversed. It is not clear if the actual numbers were altered, or only the labels about gender or sex. But Freilich and Kesselheim said the distinction is important because some people will respond to surveys differently based on each term. That can undermine the quality of the data and lead researchers to draw inaccurate conclusions, they said. They described the undisclosed changes as a 'crisis' that could make US data 'untrustworthy and unusable'. They called on governments elsewhere in the world to invest in other data sources.


Health Line
3 hours ago
- Health Line
What to Know About Homeopathic Remedies for Eczema
Key takeaways Relying solely on homeopathic remedies for eczema may not provide adequate relief. Studies show inconsistent or nonsignificant results compared to placebos. Although scientific backing is limited, homeopathic remedies like dulcamara, graphites, pine tar, and sulfur may help you manage eczema symptoms like itching, inflammation, and skin hydration. Health organizations and the FDA caution against using homeopathy for eczema due to limited safety and efficacy data. Consult a healthcare professional for proven treatments like antihistamines and steroids. Many people with eczema find it challenging to manage the condition. Because eczema is chronic and causes intermittent flare-ups, some people seek different interventions — including alternative treatment approaches like homeopathy. But can homeopathy treat or cure eczema? Homeopathy is a form of complementary or alternative medicine that uses small, diluted doses of a natural substance that causes symptoms to treat those symptoms. The belief is that if large quantities of a substance cause symptoms of a disease, a small, properly diluted amount can help the body heal itself. Some people tout homeopathy as a remedy for eczema, an inflammatory skin condition that affects an estimated 223 million people worldwide. But there's hardly any solid scientific evidence that supports the use or effectiveness of homeopathy for treating eczema. Read on to find out what research says about the use of homeopathy for eczema, if homeopathic products are FDA-approved, and the potential risks of using homeopathy for eczema. Can homeopathy help treat eczema? One of the earliest studies on homeopathy for eczema was a 2009 study by German researchers. The study compared the effects of homeopathic remedies versus placebo in young adults ages 18–35 with eczema. The study found no significant difference between the group that received homeopathy and the group that received a placebo. A later review of studies analyzed evidence from controlled clinical trials for homeopathic treatment for all types of eczema. The research indicated that no evidence from the controlled trials proved the efficacy of homeopathy for treating eczema. A more recent, small 2022 preliminary study noted a slight improvement in eczema symptoms among people who used homeopathy compared to placebo, but the difference was not statistically significant. This means the researchers weren't confident that the slight improvement they observed wasn't by chance. Some homeopathy advocates believe homeopathy can help relieve stress and anxiety, which triggers eczema flare-ups in some people. But a systematic review has shown inconsistent results for its effectiveness in treating anxiety. What do the experts say? The U.S.-based National Eczema Association and U.K.-based National Eczema Society both caution that there's not enough research to support using alternative treatments like homeopathy. Other international organizations like the Polish Dermatological Society also don't recommend using homeopathy for treating eczema. What homeopathic remedies do people use to treat eczema? Although the National Eczema Association cautions that there's not enough research to support alternative therapies like homeopathy, it notes that about half of people with eczema use these treatments. Here are some homeopathic remedies some people believe can help with eczema: Dulcamara Dulcamara, also called woody nightshade, is a shrubby perennial plant from the Solanaceae family. It's a medicinal plant touted for treating skin conditions. While scientific evidence for this is sparse, 2021 research indicated that the plant is rich in alkaloids, has antibacterial properties, and is traditionally used for relieving mild recurrent eczema. Graphites Graphite is a carbon compound similar to coal. Some people use it to treat dry, cracked, itchy, red skin, as occurs in eczema. A 2020 case report revealed that graphite helped reduce eczema symptoms after several weeks of treatment. Pine tar (pix liquida) Studies suggest a potential benefit of using pine tar to treat skin conditions like eczema and psoriasis. People produce pine tar by high-temperature carbonization of the pine tree wood. A 2022 study suggested it may help relieve eczema symptoms, reduce inflammation, and lower the risk of infection. Sulfur Other remedies Other homeopathic remedies with little to no scientific backing include: Rhus toxicodendron sepia natrum muriaticum mezereum lycopodium Arsenicum album Calcarea carbonica Mercurius solubilis barberry (Berberis vulgaris) Are homeopathic products FDA-approved? The Food and Drug Administration (FDA) does not approve any homeopathic product for treatment because the agency has not determined that such products meet effectiveness, safety, and quality standards. What are the risks of homeopathy for eczema? An older review of case reports reported the following side effects of homeopathy: allergic reaction widespread skin irritation nausea and vomiting skin itching hair loss sneezing and inflammation of the nasal cavity lining (rhinitis) Also, keep the following in mind when using homeopathic products: No government body or agency legally regulates homeopathic practitioners. This means a person without qualifications can claim to be a homeopath. There's no strong scientific evidence that homeopathy is safe or effective for eczema. Some homeopathic products may contain high amounts of substances that are not good for your health. A homeopathic product may interfere with your doctor's prescribed medication, reducing its efficacy or causing side effects. What natural and alternative treatments can help with eczema? Some natural treatments that may help manage eczema include: Acupuncture: Acupuncture, part of Traditional Chinese Medicine (TCM), may help reduce skin itching, wheal size, and allergic reaction in people with eczema. Aloe vera: Aloe vera is a plant rich in antioxidants that can help heal wounds, regenerate damaged skin, and retain skin integrity. Coconut oil: Some people with eczema may benefit from coconut oil because it has antimicrobial and anti-inflammatory properties, hydrates the skin, reduces itching, and reduces the chances of infection. Colloidal oatmeal: Colloidal oatmeal is oat grain ground into a fine powder. It can help your body retain moisture and relieve dry, itchy skin. Honey: Researchers have observed several properties of honey that may help people with eczema, but more research is needed. Massage therapy: A gentle, 20-minute massage using a moisturizer may help reduce eczema symptoms by reducing stress and encouraging blood flow. Sunflower seed oil: Sunflower oil contains vitamin E, oleic acid, linoleic acid, and sesamol which are all good for your skin. It can help repair your skin barrier and reduce inflammation. Tea tree oil: Tea tree oil can reduce eczema symptoms because it has anti-inflammatory, antimicrobial, and antioxidant properties.
Yahoo
4 hours ago
- Yahoo
The Blueberry Recall Just Got More Serious—Here's What To Know
When the Fourth of July rolls around, there's nothing we love more than concocting the perfect, summery sweet treat. However, before you turn to the fruit aisle to grab fresh, seasonal strawberries and blueberries to bring to life that festive American flag cake that's every Pinterest lover's dream or that refreshing fruit salad, think twice. The FDA has issued a recall of hundreds of boxes of blueberries. Here, everything we know and what you ought to know ahead of the holiday weekend. Back in early June, a recall was issued by Georgia-based company Alma Pak International LLC for hundreds of boxes of organic blueberries. As stated by the initial report, the recall came to be when, during routine testing, the product tested positive for Listeria monocytogenes. In total, 400 30-pound boxes were part of this recall, identifiable by Lot numbers 13325 G1060 and 13325 G1096. The voluntary recall stated that these products were shipped to one customer in North Carolina. Though it was on June 9 that this recall was first issued, on July 1, the FDA elevated this situation to a Class I threat. As stated by their website, a Class I recall is 'a situation in which there is a reasonable probability that the use of or exposure to a violative product will cause serious adverse health consequences or death.' While there have yet to be any reports of people falling ill after consuming this particular recalled product, vigilance is key when it comes to food safety. Over the last year, listeria is the word that's been circulating when it comes to recalls, and the symptoms can range from mild to severe. According to the FDA's website, the less severe version of the illness is non-invasive and usually will result in side effects like nausea, vomiting, fever, aches and diarrhea. On the contrary, the invasive version can be fatal. 'Symptoms may include headache, stiff neck, confusion, loss of balance, and convulsions,' says the FDA website. 'Invasive listeriosis is a potentially life-threatening event, especially for newborns, adults over the age of 65, and those with weakened immune systems.' If you think you might have consumed contaminated food, it's best to see your healthcare provider and monitor symptoms. If you start to feel any of the symptoms listed above, seek medical guidance. In a statement to Newsweek, the company revealed that the recall was issued before blueberries even hit shelves, meaning no customers consumed these contaminated products, and therefore, no one was at risk. They continued, 'The company worked in close coordination with the U.S. Food and Drug Administration (FDA), the Georgia Department of Agriculture, and an independent food safety consultant to conduct a thorough investigation. Alma Pak International has implemented additional corrective actions and preventive controls to further strengthen its already rigorous food safety systems.' Looking for more trending stories? Click through below! Could '1969' Be the Next 'Yellowstone' Series? Rumors Fly About a Prequel Between '1944' and Today From Tax Breaks to Medicaid Cuts: What the 'Big Beautiful Bill' Means for Americans 50+ Paula Deen's 5 Favorite Fourth of July Recipes—Drinks, Desserts & Deviled Eggs, Oh My! (EXCLUSIVE)